USANA Health Sciences Inc (USNA)
Official siteCONSUMER DEFENSIVE • PACKAGED FOODS • NYSE
Market Cap: $244.79M
Last updated: Nov 17, 2026 at 11:06 AM ET
USANA Health Sciences Inc (USNA) Earnings: Report Dates and Results
USANA Health Sciences (USNA) is expected to report earnings on Feb 10, 2027. In the quarter ended Sep 30, 2026, USANA Health Sciences reported EPS of -$0.11, below the $0.11 estimate. It beat the EPS estimate in 5 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
USNA has an expected report date of Feb 10, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 80.0% below the $0.60 reported for the quarter ended Dec 31, 2025.
USNA Earnings Call
The latest USNA earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, USNA beat 27, missed 12 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $205.88M, down 3.6% from $213.67M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.11 | $0.11 | $0.11 - $0.11 | -200.00% | Miss | N/A | 1 | 0 up, 1 down | Nov 3, 2026 | $205.88M |
| Jun 30, 2026 | -$0.07 | $0.43 | $0.43 - $0.43 | -116.28% | Miss | -109.5% | 1 | 0 up, 1 down | Aug 4, 2026 | $223.27M |
| Mar 31, 2026 | $0.61 | $0.44 | $0.44 - $0.44 | +38.64% | Beat | -16.4% | 1 | 1 up, 0 down | May 5, 2026 | $250.22M |
| Dec 31, 2025 | $0.60 | $0.41 | $0.41 - $0.41 | +46.34% | Beat | -6.3% | 1 | 1 up, 0 down | Feb 17, 2026 | $226.20M |
| Sep 30, 2025 | -$0.15 | -$0.15 | -$0.15 - -$0.15 | 0.00% | In line | -126.8% | 1 | 0 up, 1 down | Oct 21, 2025 | $213.67M |
| Jun 30, 2025 | $0.74 | $0.54 | $0.54 - $0.54 | +37.04% | Beat | +37.0% | 1 | 0 up, 1 down | Jul 22, 2025 | $235.85M |
| Mar 31, 2025 | $0.73 | $0.70 | $0.70 - $0.70 | +4.29% | Beat | -15.1% | 1 | 0 up, 1 down | Apr 22, 2025 | $249.54M |
| Dec 31, 2024 | $0.64 | $0.49 | $0.49 - $0.49 | +30.61% | Beat | -26.4% | 2 | 0 up, 1 down | Feb 25, 2025 | $213.61M |
| Sep 30, 2024 | $0.56 | $0.49 | $0.46 - $0.51 | +14.29% | Beat | -5.1% | 2 | 0 up, 0 down | Oct 22, 2024 | $200.22M |
| Jun 30, 2024 | $0.54 | $0.65 | $0.62 - $0.68 | -16.92% | Miss | -39.3% | 2 | 0 up, 0 down | Jul 23, 2024 | $212.87M |
| Mar 31, 2024 | $0.86 | $0.69 | $0.63 - $0.75 | +24.64% | Beat | -9.5% | 2 | 0 up, 0 down | Apr 30, 2024 | $227.80M |
| Dec 31, 2023 | $0.87 | $0.52 | $0.50 - $0.53 | +67.31% | Beat | +31.8% | 2 | 0 up, 0 down | Feb 6, 2024 | $221.08M |
| Sep 30, 2023 | $0.59 | $0.64 | $0.60 - $0.67 | -7.81% | Miss | -24.4% | 2 | 0 up, 0 down | Oct 24, 2023 | $213.37M |
| Jun 30, 2023 | $0.89 | $0.70 | $0.62 - $0.77 | +27.14% | Beat | -11.0% | 2 | 0 up, 0 down | Jul 25, 2023 | $238.20M |
| Mar 31, 2023 | $0.95 | $0.77 | $0.77 - $0.77 | +23.38% | Beat | -17.4% | 1 | 0 up, 0 down | Apr 25, 2023 | $248.36M |
| Dec 31, 2022 | $0.66 | $0.35 | $0.35 - $0.35 | +88.57% | Beat | -35.9% | 1 | 0 up, 0 down | Feb 7, 2023 | $227.96M |
| Sep 30, 2022 | $0.78 | $0.89 | $0.89 - $0.89 | -12.36% | Miss | -42.6% | 1 | 0 up, 0 down | Oct 25, 2022 | $233.30M |
| Jun 30, 2022 | $1.00 | $1.05 | $1.05 - $1.30 | -4.76% | Miss | -46.5% | 3 | 0 up, 1 down | Jul 26, 2022 | $264.47M |
| Mar 31, 2022 | $1.15 | $1.14 | $1.13 - $1.15 | +0.88% | Beat | -20.7% | 3 | 0 up, 0 down | Apr 26, 2022 | $272.87M |
| Dec 31, 2021 | $1.03 | $1.28 | $1.26 - $1.30 | -19.53% | Miss | -44.9% | 2 | N/A | Feb 8, 2022 | $267.30M |
| Sep 30, 2021 | $1.36 | $1.35 | N/A | +0.74% | Beat | -5.6% | 2 | 0 up, 0 down | Oct 26, 2021 | $274.35M |
| Jun 30, 2021 | $1.87 | $1.78 | $1.65 - $1.78 | +5.06% | Beat | +41.7% | 2 | N/A | Jul 27, 2021 | $336.84M |
| Mar 31, 2021 | $1.45 | $1.57 | $1.40 - $1.57 | -7.64% | Miss | +17.9% | 2 | N/A | Apr 27, 2021 | $307.98M |
| Dec 31, 2020 | $1.87 | $1.39 | $1.31 - $1.51 | +34.53% | Beat | +32.6% | 3 | N/A | Feb 9, 2021 | $310.52M |
| Sep 30, 2020 | $1.44 | $1.29 | N/A | +11.63% | Beat | +32.1% | 2 | N/A | Oct 20, 2020 | $298.51M |
| Jun 30, 2020 | $1.32 | $1.19 | $0.97 - $1.19 | +10.92% | Beat | +45.1% | 2 | N/A | Jul 21, 2020 | $258.99M |
| Mar 31, 2020 | $1.23 | $0.57 | $0.57 - $1.10 | +115.79% | Beat | +21.8% | 2 | N/A | Apr 21, 2020 | $266.62M |
| Dec 31, 2019 | $1.41 | $0.98 | $0.98 - $0.99 | +43.88% | Beat | +6.8% | 2 | N/A | Feb 4, 2020 | $271.30M |
| Sep 30, 2019 | $1.09 | $0.87 | $0.84 - $0.90 | +25.29% | Beat | -12.1% | 3 | N/A | Oct 22, 2019 | $260.60M |
| Jun 30, 2019 | $0.91 | $0.93 | $0.91 - $0.94 | -2.15% | Miss | -33.1% | 3 | N/A | Jul 23, 2019 | $256.02M |
| Mar 31, 2019 | $1.01 | $0.99 | $0.98 - $1.00 | +2.02% | Beat | -15.1% | 3 | N/A | Apr 30, 2019 | $272.99M |
| Dec 31, 2018 | $1.32 | $1.29 | $1.22 - $1.41 | +2.33% | Beat | +18.9% | 3 | N/A | Feb 5, 2019 | $299.02M |
| Sep 30, 2018 | $1.24 | $1.10 | $1.04 - $1.16 | +12.73% | Beat | +21.6% | 3 | N/A | Oct 23, 2018 | $296.77M |
| Jun 30, 2018 | $1.36 | $1.11 | $1.10 - $1.16 | +22.52% | Beat | +38.8% | 2 | N/A | Jul 24, 2018 | $301.46M |
| Mar 31, 2018 | $1.19 | $1.05 | $1.03 - $1.10 | +13.33% | Beat | +38.4% | 3 | N/A | Apr 24, 2018 | $292.00M |
| Dec 31, 2017 | $1.11 | $1.00 | $0.97 - $1.03 | +11.00% | Beat | +27.6% | 3 | N/A | Feb 6, 2018 | $273.11M |
| Sep 30, 2017 | $1.02 | $0.91 | $0.85 - $0.96 | +12.09% | Beat | -15.0% | 2 | N/A | Oct 24, 2017 | $261.76M |
| Jun 30, 2017 | $0.98 | $1.06 | $1.05 - $1.24 | -7.55% | Miss | -4.9% | 2 | N/A | Jul 25, 2017 | $257.06M |
| Mar 31, 2017 | $0.86 | $0.92 | N/A | -6.52% | Miss | -3.4% | N/A | N/A | May 2, 2017 | $255.32M |
| Dec 31, 2016 | $0.87 | $0.95 | N/A | -8.42% | Miss | -5.4% | N/A | N/A | Feb 7, 2017 | $252.90M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $1.92, down 26.2% from the year before. It was $3.99 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $1.92 | -26.2% |
| Dec 31, 2024 | $2.60 | -21.2% |
| Dec 31, 2023 | $3.30 | -8.1% |
| Dec 31, 2022 | $3.59 | -37.1% |
| Dec 31, 2021 | $5.71 | -2.6% |
| Dec 31, 2020 | $5.86 | +32.6% |
| Dec 31, 2019 | $4.42 | -13.5% |
| Dec 31, 2018 | $5.11 | +28.7% |
| Dec 31, 2017 | $3.97 | N/A |
| Dec 31, 2016 | $3.99 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 3,400 words across 8 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 3,440 | 8 | |
| 2026Q2 | Jun 30, 2026 | 4,404 | 10 | |
| 2026Q1 | Mar 31, 2026 | 3,587 | 9 | |
| 2025Q4 | Dec 31, 2025 | 3,609 | 9 | |
| 2025Q3 | Sep 30, 2025 | 3,996 | 10 | |
| 2025Q2 | Jun 30, 2025 | 3,925 | 8 | |
| 2025Q1 | Mar 31, 2025 | 2,637 | 8 | |
| 2024Q4 | Dec 31, 2024 | 3,631 | 10 |
2026Q3 Earnings Call
Opening remarks
Andrew Masuda Director of Investor Relations Thank you, and good morning, everyone. We appreciate you joining us to review our third quarter results. Today's conference call is being broadcast live via webcast and can be accessed directly from our website at ir.usana.com. Shortly following the call, a replay will be available on our website. As a reminder, during the course of this conference call, management will make forward-looking statements regarding future events or the future financial performance of our company. Those statements involve risks and uncertainties that could cause actual results to differ materially from the results projected in such forward-looking statements. Examples of these statements include those regarding our strategies and outlook for fiscal year 2026, uncertainty related to the economic and operating environment around the world, and our operations and financial results. We caution you that these statements should be considered in conjunction with disclosures, including specific risk factors and financial data contained in our most recent filings with the SEC. During today's call, we will also refer to certain non-GAAP financial measures, including adjusted EBITDA and free cash flow. Reconciliations of these measures to the most directly comparable GAAP measures are included in our earnings release. I'm joined by our Chairman and Chief Executive Officer, Kevin Guest; our Chief Financial Officer, Doug Hekking; our Chief Commercial Officer, Brent Neidig; our Chief Operating Officer, Walter Noot; our Chief Scientific Officer, Dr. Kathryn Armstrong; and other executives. Yesterday, after the market closed, we announced our third quarter results and posted our management commentary document on the company's website. We'll now hear brief remarks from Kevin and Doug before opening the call for questions.
Kevin Guest Chairman and Chief Executive Officer Thank you, Andrew, and good morning, everyone. I'd like to speak to the strategy we're executing, where we're seeing progress, and where we still have work to do. Our earnings release and management commentary present the numbers for the business. So I'll focus on providing context for the numbers and then ask Doug to add more color on how our strategy is coming to fruition. Overall, this was a mixed quarter, but one where I'm encouraged by the progress we're seeing with our strategy. Our strategy is to evolve USANA from a single-channel direct-selling company into a diversified omnichannel health and wellness company built on consumer acquisition and loyalty. In Core Nutrition, we're working to increase customer acquisition and customer loyalty by investing in the USANA brand, bringing new products to market, and further refining our incentive structure. Through Hiya and Rise Wellness, we're expanding our business to reach consumers at more venues where they already shop, including retail and Amazon. Our debt-free balance sheet lets us fund this expansion with discipline. Let me start with what's working.
Frequently Asked Questions About USNA
When is USANA Health Sciences's next earnings date?
USANA Health Sciences's next earnings report is expected for Feb 10, 2027.
Did USNA beat earnings estimates last quarter?
No. USANA Health Sciences reported EPS of -$0.11 for the quarter ended Sep 30, 2026, below the $0.11 estimate by 200.00%.
What EPS do analysts expect from USNA next quarter?
The consensus EPS estimate for USANA Health Sciences for the quarter ending Dec 31, 2026 is $0.12 from 3 analysts, with estimates from $0.12 to $0.13.
How often does USNA beat earnings estimates?
USANA Health Sciences beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of -19.92%.
USNA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors